A late-stage hit with its respiratory syncytial virus jab would be a huge validation for the group’s new focus.
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
Positive phase 2 data with the group’s maternal RSV vaccine set up a busy 2022 for work on the infectious disease.
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.